Clinical trial

#AI #Cancer research #Cervical cancer #Clinical trial #Colorectal cancer #Genetics / genomics #Head and neck cancer #MHRA #Obesity #Pistoia Alliance #Precision medicine #University College London #University of Cambridge #Weight loss

DDW Highlights: 9 June 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, a cancer drug demonstrated it could reduce tumours by as much as… Read More

#Podcasts

#AI #Cancer research #Cervical cancer #Clinical trial #Colorectal cancer #Genetics / genomics #Head and neck cancer #MHRA #Obesity #Pistoia Alliance #Precision medicine #University College London #University of Cambridge #Weight loss

This week in Drug Discovery (1 June – 5 June) 

News round-up for 1 June – 5 June by Bruno Quinney, Content Team at DDW.  This week, a cancer drug has demonstrated it could reduce tumours by as much as 55%. Elsewhere, AI has been a recurrent theme in both clinical trials and drug development.   The top stories:… Read More

#News

Johnson & Johnson head office
#Clinical trial #Johnson & Johnson

Treatment for SLE significantly reduces disease activity 

A new treatment for systemic lupus erythematosus (SLE) could significantly reduce disease activity, results show.  Johnson & Johnson, which developed nipocalimab, says it is the first neonatal Fc receptor (FcRn) blocker to be studied in systemic lupus erythematosus. The blocker is designed to target and reduce pathogenic immunoglobulin… Read More

#News

#AI #Clinical trial #MHRA

First AI drug enters clinical development 

The first oral drug formulated by AI has been advanced into clinical development.  CRDMO Quotient Sciences has announced a Phase I study of the drug was initiated at the company’s UK facility following approval from the Medicines and Healthcare products Regulatory Agency (MHRA).   The study will… Read More

#News

#Clinical trial #Immunic Therapeutics #MS #Multiple sclerosis

Immunic appoints Erik Lundgren as CEO 

Biotechnology company Immunic Therapeutics has appointed Erik Lundgren as Chief Executive Officer.  Immunic says Lundgren will lead the company as it advances vidofludimus calcium through late-stage clinical development. Vidofludimus calcium has shown therapeutic activity in Phase II clinical trials in relapsing-remitting multiple sclerosis, progressive multiple sclerosis and other diseases.  Lundgren recently served… Read More

#News

AI clinical trials concept
#AI #Clinical trial #Pistoia Alliance

Trust and regulation holding back AI in clinical trials 

The use of AI in clinical trials is being held back by a lack of trust and regulatory uncertainty, professionals say.  A poll from The Pistoia Alliance found that half of respondents agreed trust and regulatory uncertainty were barriers to AI adoption in clinical trials. … Read More

#News

Kidneys
#Clinical trial #EMA #Hansa Biopharma #Transplant

Hansa Biopharma reports positive PAES results from Idefirix 

Hansa Biopharma has announced positive topline results from a study investigating Idefirix (imlifidase) in patients who have undergone HLA-incompatible kidney transplantation.  The biopharmaceutical company announced the primary objective of the post-authorisation efficacy study (PAES) was met, with 90% of highly sensitised kidney transplant patients achieving one‑year graft failure‑free survival – following Idefirix pre‑treatment to convert… Read More

#News

Scientist using a laptop
#Biotech #CDMO #Clinical trial

Biotech reliance on large CDMOs could cause overruns of 40% 

Overreliance of biotechs on large CDMOs could cause overruns of up to 40%, an industry expert has warned.  Madhav Bhutada, Director of Shilpa Biologicals, urged biotechs to take a broader and earlier approach to CDMO selection as funding conditions improve across the sector.   Bhutada said many emerging biopharma innovators –… Read More

#News

Human liver
#Clinical trial #Liver disease #University of Edinburgh

Research suggests RMT could treat end-stage liver disease 

A pioneering Regenerative Macrophage Therapy (RMT) could represent a new method of treating end-stage liver disease, research shows.  Results from the University of Edinburgh’s MATCH trial, published in Cell Stem Cell, demonstrate RMT provides significantly prolonged transplant‑free survival after four years compared with those who received standard care. Read More

#News

Soft tissue sarcoma
#Clinical trial #RNA modifying enzymes #Sarcoma

Enzyme inhibitor shows early evidence of treating sarcoma 

An RNA-modifying enzyme inhibitor has shown positive results in treating sarcoma patients during a Phase I trial.  STC-15, developed by STORM Therapeutics, demonstrated a disease control rate of 54% at 12 weeks and a median progression-free survival of six months. The trial enrolled 42 patients with advanced… Read More

#Cancer Research #News

Human heart
#Cardiometabolic diseases #Clinical trial #HAYA Therapeutics #Phase I trial

First patients dosed in hypertrophic cardiomyopathy trial

HAYA Therapeutics has dosed the first cohort in a Phase I trial evaluating a treatment for nonobstructive hypertrophic cardiomyopathy (nHCM).  The Swiss biotechnology company is studying HTX-001, a differentiated and potentially disease-modifying approach to treating patients with nHCM.   The investigational molecule is an antisense oligonucleotide… Read More

#News

#AI #Autoimmune disease #Breast cancer #Clinical trial #Cystic fibrosis #Diabetes #FDA #Fractyl Health #Gene therapy #GLP-1 #Institute of Cancer Research #Oncology #Phesi

This week in Drug Discovery (18 – 22 May)

News round-up for 18 – 22 May by Bruno Quinney, Content Team at DDW.    This week, a report showed patients in Europe face barriers to patient access. Elsewhere, Wellcome prizes are facilitating research in both tropical disease and mental health.    The… Read More

#News

Laboratory research
#Advanced Therapies #Clinical trial #UK

UK introduces framework for advanced therapy trials 

The UK is set to introduce a national framework to boost advanced therapy clinical trials.  The Advanced Therapy Clinical Trials Capability Framework, produced jointly by the Advanced Therapy Treatment Centre (ATTC) network, the Cell and Gene Therapy Catapult and Skills for Health, provides a shared strategic resource… Read More

#News

Scientist in laboratory
#AI #Clinical trial #iOnctura #Poolbeg Pharma #Regulatory #Synklino #Weatherden

Expert opinion: Navigating the challenges in the clinical trials sector

On International Clinical Trials Day, industry experts speak to DDW about the current state of play within global clinical trials. DDW: How encouraged are you by regulatory reforms – whether it’s a focus on the use of NAMs, or faster regulatory review processes – to help companies conduct more efficient and effective trials? Liam Tremble: A lot… Read More

#Exclusive Content #Regulatory

Medical laboratory
#Bispecific Antibodies #Cancer research #Clinical trial

Mestag doses first patient in treatment for solid tumours 

Mestag Therapeutics has dosed the first patient in its Phase I trial evaluating a novel therapeutic strategy to treat solid tumours.  MST-0312 is a bispecific antibody designed to activate lymphotoxin-beta receptor (LTBR) in the tumour microenvironment to induce the formation of tertiary lymphoid structures (TLS) and associated high… Read More

#Cancer Research #News

#AI #Autoimmune disease #Breast cancer #Clinical trial #Cystic fibrosis #Diabetes #FDA #Fractyl Health #Gene therapy #GLP-1 #Institute of Cancer Research #Oncology #Phesi

DDW Highlights: 19 May 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, research uncovered new treatment pathways for hard to treat breast cancers. Elsewhere,… Read More

#Podcasts